Local Recurrence in Choroidal Melanomas following Robotic-Assisted Radiosurgery (CyberKnife)
Discussion: Robotic-assisted radiosurgery (CyberKnife) is a suitable treatment option for large choroidal melanoma up to 12 mm. Patients with significantly better visual acuity received repeat CyberKnife treatment as salvage therapy and showed an eye retention rate of 81%.Ocul Oncol Pathol 2022;8:221 –229 (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - November 7, 2022 Category: Opthalmology Source Type: research
Local Recurrence in Choroidal Melanomas following Robotic-Assisted Radiosurgery (CyberKnife)
Discussion: Robotic-assisted radiosurgery (CyberKnife) is a suitable treatment option for large choroidal melanoma up to 12 mm. Patients with significantly better visual acuity received repeat CyberKnife treatment as salvage therapy and showed an eye retention rate of 81%. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - November 7, 2022 Category: Opthalmology Source Type: research
Local recurrence in choroidal melanomas following Robotic assisted Radiosurgery (CyberKnife)
Discussion: Robotic assisted radiosurgery (CyberKnife) is a suitable treatment option for large choroidal melanoma up to 12mm. Patients with significantly better visual acuity received repeat Cyberknife treatment as salvage therapy and showed an eye retention rate of 81%. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - November 7, 2022 Category: Opthalmology Source Type: research
Serous Choroidal Detachment and Scleritis Associated with Necrotic Choroidal Tumors
Conclusion: Choroidal detachment with concurrent scleritis can occur as rare sequelae of tumor necrosis of an
underlying choroidal malignancy. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - November 4, 2022 Category: Opthalmology Source Type: research
Anterior Uveal Melanocytoma: Role of Diagnostic FNAB
Conclusion:
FNAB offers a minimally invasive and safe diagnostic approach for pathologic confirmation of AUM. However, limitations of FNAB including false-negative and false-positive biopsies must be considered when excluding underlying malignancy. Continued observation to document tumor stab ility should be considered. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - October 19, 2022 Category: Opthalmology Source Type: research
A Case Series of Aggressive Orbital Plasmacytomas
Discussion
It is important to pe rform systemic evaluation and appropriate treatment immediately once the diagnosis has been established. This case series aimed to increase awareness of orbital plasmacytoma existence and consider it as one of the differential diagnosis in orbital tumor. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - October 12, 2022 Category: Opthalmology Source Type: research
Recurrence of Primary Acquired Melanosis and Conjunctival Intraepithelial Neoplasia
Conclusion: With the strategy of radical treatment for CIN and PAM with atypia, whenever possible, subsequent follow-up can probably be ceased after 10 years if the patient is not immunocompromised. For completely excised PAM with atypia grade I, there is most likely no need for further clinical controls. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - September 14, 2022 Category: Opthalmology Source Type: research
Recurrence of primary acquired melanosis and conjunctival intraepithelial neoplasia.
Conclusion
With the strategy of radical treatment of CIN and PAM with atypia whenever possible subsequent follow up can probably be ceased after ten years if the patient is not immunocompromised. For completely excised PAM with atypia grade I there is most likely no need for further clinical controls. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - September 14, 2022 Category: Opthalmology Source Type: research
Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept
Conclusion: This pilot study suggests that patients with radiation retinopathy who have failed monthly intravitreal bevacizumab may respond to aflibercept. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - September 1, 2022 Category: Opthalmology Source Type: research
Outcomes of second line intravitreal anti-VEGF switch therapy in radiation retinopathy secondary to uveal melanoma: moving from bevacizumab to aflibercept
Conclusion: This pilot study suggests that patients with radiation retinopathy who have failed monthly intravitreal bevacizumab may respond t o aflibercept. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - September 1, 2022 Category: Opthalmology Source Type: research
Uveitic Granulomas Masquerading as Ocular Tumors
Conclusions: Uveitic granulomas can demonstrate features of ocular tumors. Proper uveitis management leads to a favorable visual outcome and ocular preservation. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - September 1, 2022 Category: Opthalmology Source Type: research
Comparative Metastatic Rates in GEP Class 1A versus 1B Posterior Uveal Melanoma: Results Contrary to Expectations
Conclusion: The results of this retrospective single-center study cast doubt on the validity of the prognostic stratification of GEP class 1 posterior uveal malignant melanomas into very low risk (GEP 1A) versus intermediate risk (GEP 1B) of metastasis subgroups provided by the commercially available GEP test.Ocul Oncol Pathol (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - August 31, 2022 Category: Opthalmology Source Type: research
Comparative Metastatic Rates in GEP Class 1A versus 1B Posterior
Uveal Melanoma. Results Contrary to Expectations.
Conclusion: The results of this retrospective single-center study cast doubt on the validity of the prognostic stratification of GEP class 1 posterior uveal malignant melanomas into very low risk (GEP 1A) versus intermediate risk (GEP 1B) of metastasis subgroups provided by the commercially available GEP test. (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - August 31, 2022 Category: Opthalmology Source Type: research
Predictors of Local Recurrence and Progression-Free Survival in Iodine-125 brachytherapy-treated Uveal Melanomas: A modern institutional study
Introduction: Iodine-125 brachytherapy is an effective eye-sparing treatment for uveal melanoma. Previous work has shown that uveal melanomas cluster into distinct molecular classes based on gene expression profiles —discriminating low-grade from high-grade tumors. Our objective was to identify clinical and molecular predictors of local recurrence (LR) and progression-free survival (PFS).
Methods: We constructed a retrospective database of uveal melanoma patients from the University of Miami’s electronic me dical records that were treated between 8/1/2012-5/1/2019, with either COMS-style or Eye Physics plaque. Data on ...
Source: Ocular Oncology and Pathology - August 29, 2022 Category: Opthalmology Source Type: research
Post-Brachytherapy Pigment Dispersion in Uveal Melanoma
No structured abstract required for letter (Source: Ocular Oncology and Pathology)
Source: Ocular Oncology and Pathology - July 22, 2022 Category: Opthalmology Source Type: research
